Osiris partners with Arthrex for the exclusive commercialisation and development of the cartilage product Cartiform.
M2 EQUITYBITES-October 20, 2014-Osiris partners with Arthrex for the exclusive commercialisation and development of the cartilage product Cartiform
(C)2014 M2 COMMUNICATIONS http://www.m2.com
Regenerative medicine company Osiris Therapeutics (NasdaqGM:OSIR) reported on Friday the launch of an exclusive commercial and development partnership for Cartiform with Arthrex, a medical device company in orthopaedics and sports medicine.
According to Osiris, Cartiform is a viable chondral allograft that promotes articular cartilage repair to treat focal chondral defects and combines the safety and proven success of fresh osteochondral allografts with ease of use resulting from its proprietary cryopreservation technology. It is stored at -80 degrees Celsius with a two year shelf life and can be implanted in a single step procedure.
In addition, Cartilage has limited ability to self-repair and the current standard of care, microfracture or bone marrow stimulation, remains unsatisfactory. It combines distinct clinical advantages of fresh stored allograft with the logistical and delivery advantages of non-viable, point of care implants, said Osiris.
Pursuant to the agreement, Arthrex receives the exclusive commercial distribution rights to Cartiform. Osiris will be responsible for the manufacturing, continued research and product improvement activities. The design and conduct of future clinical development programmes will be shared between both organisations.
((Comments on this story may be sent to email@example.com))
|Printer friendly Cite/link Email Feedback|
|Publication:||M2 EquityBites (EQB)|
|Date:||Oct 20, 2014|
|Previous Article:||Northern Trust opens office in South Korea.|
|Next Article:||China Biologic to begin commercial manufacturing of human prothrombin complex concentrate at Shandong Taibang Facility.|